| Market Cap | ₹121.53 CrSmall Cap |
|---|---|
| P/E Ratio TTM | 29.54xSector: 43.58x |
| 1-Year Return | 42.52%Annual Growth |
| Deal value | ₹4.45 Cr |
| Share of market cap | 3.7% |
| Share of annual revenue | 4.0% |
Key highlights
- Allotment of 66,667 equity shares upon conversion of an equal number of warrants on November 17, 2026
- Promoter's direct equity holding increased from 0.61% to 1.14% of the post-allotment voting capital
- Total diluted shareholding including remaining warrants stands at 1.60% of the company
- Post-allotment equity share capital stands at ₹11.70 crore divided into 1.17 crore fully paid shares
- Transaction follows a ₹44.12 crore preferential capital raise initiated to fund API manufacturing capex
Conversion Details and Promoter Holding Expansion
Godavari Drugs Limited has finalized the allotment of 66,667 equity shares to promoter Ieshir Jaju, following the conversion of an equivalent number of convertible warrants. This exercise of rights, completed on November 17, 2026, increased the promoter's shareholding from 66,667 to 133,334 equity shares. On a fully diluted basis, which accounts for all remaining warrants, the promoter's total interest now comprises 2,00,000 units, representing 1.60% of the company's expanded capital.
This move follows a larger allotment of 7,86,690 shares to the promoter category earlier in the month, underscoring continued capital support from the founding group during the company's current expansion phase.
Capital Restructuring and Operational Milestones
- Equity share capital increased to ₹11,70,08,150 divided into 1,17,00,815 fully paid-up shares
- Total diluted share capital post-acquisition stands at 1,24,87,500 equity shares of ₹10 each
- Company secured a ₹34.00 crore working capital credit facility from ICICI Bank in October 2026
- Standalone revenue for Q2 FY2027 reached ₹28.23 crore with a 9.91% operating profit margin
- Management reported plant trials for DHDT, an anti-HIV drug intermediate, were almost completed in September
- Shareholders approved an expansion into nutraceuticals and dietary supplements at the 38th AGM
Strategic Diversification into Nutraceuticals
The company is actively diversifying its business model beyond generic API manufacturing into the high-growth nutraceuticals sector. In October 2026, Godavari Drugs received a fresh certificate from the MCA confirming its updated Corporate Identification Number after altering its Main Objects Clause. This strategic shift is backed by a ₹44.12 crore fundraise via preferential issues to fund both API capacity and the new dietary supplements vertical.
While annual revenue saw a slight decline of 6.75% in the previous fiscal, recent quarterly performance shows a stabilization in margins, supported by the anticipated commencement of commercial production for new drug intermediates.
| Date | Announcement | Amount |
|---|---|---|
| 11 Nov 2026 | Approval of un-audited standalone financial results for the quarter and half-year ended 30 September 2026Source: BSE filing | – |
| 05 Nov 2026 | Allotment of 7,86,690 equity shares to promoter category upon conversion of warrantsSource: market data.com | ₹5.25 Cr |
| 16 Oct 2026 | Receipt of MCA certificate confirming change of Corporate Identification Number to L21001TG1987PLC008016 following object clause alterationSource: BSE filing | – |
| 14 Oct 2026 | Board approval for availing working capital credit facilities from ICICI Bank LimitedSource: BSE filing | ₹34.00 Cr |
| 25 Sep 2026 | Shareholders approved alteration of Main Objects Clause to expand into nutraceuticals and dietary supplements at 38th AGMSource: BSE filing | – |
| 31 Aug 2026 | Board approved alteration of Main Objects Clause of Memorandum of Association to enter nutraceutical sectorSource: BSE filing | – |
What to watch next
- Commencement of commercial supplies for DHDT anti-HIV drug intermediate, expected shortly
- Operational rollout of the nutraceuticals and dietary supplements vertical following plant trials
- Financial results for the quarter ending December 31, 2026, typically announced in February 2027
| Share price | ₹120 |
|---|---|
| Market capitalisation | ₹121.53 Cr |
| Revenue (annual) | ₹105.81 Cr |
| Net profit (annual) | ₹4.09 Cr |
| Revenue (latest quarter) | ₹28.23 Cr+0.96% vs previous quarter |
| Net profit (latest quarter) | ₹0.96 Cr-13.70% vs previous quarter |
| P/E (TTM) | 29.54×Sector 43.58× |
| Promoter holding | 44.54%+4.31% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Godavari Drugs Limited announcing the conversion of warrants into equity shares by the promoter group. Market figures from a third-party data provider.




